Document Detail

Therapeutic potential of fucoidan in myocardial ischemia.
MedLine Citation:
PMID:  22146406     Owner:  NLM     Status:  In-Data-Review    
ABSTRACT: Fucoidan, a sulfated polysaccharide extracted from brown seaweed, is a candidate for the treatment of ischemic diseases. The aim of this study was to measure the therapeutic potential of fucoidan in a rat model of myocardial ischemia-reperfusion injury. Forty rats were submitted to myocardial ischemia-reperfusion injury by transient occlusion of the left coronary artery. Rats were then randomized into 2 groups: fucoidan (5 mg/kg, intramuscularly; n = 20) or control (saline intramuscularly; n = 20) was administered 1 hour before injury and daily thereafter for 1 month. At 1 month, plasma levels of stromal cell-derived factor-1α (SDF-1α) were assessed by enzyme-linked immunosorbent assay kit. Hearts were evaluated by histoimmunochemistry. Fucoidan induced significant antifibrotic effects, reducing the infarct scar size by almost 30% on Sirius red-stained sections (9.45% ± 4.27% vs. 13% ± 5.67% in controls; P = 0.03). Vascular density in the fucoidan group (α-actin, RECA-1, or lectin BS1 stained) was increased by 40% (2.18 ± 0.79 mm vs. 1.49 ± 0.42 mm in controls ×200; P = 0.001). Plasma SDF-1α at 1 month was not significantly different between the 2 groups. However, increased immunostaining density of SDF-1α and vascular endothelial growth factor in fibrotic ischemic tissues was observed in fucoidan-treated animals versus controls. In conclusion, fucoidan enhanced tissue repair in myocardial ischemia-reperfusion by promoting revascularization (in situ vascular endothelial growth factor and SDF-1α overexpression) and limiting fibrosis. Consequently, fucoidan may be useful for myocardial ischemic patients.
Stéphane Manzo-Silberman; Liliane Louedec; Olivier Meilhac; Didier Letourneur; Jean-Baptiste Michel; Ibrahim Elmadbouh
Related Documents :
18515916 - Screening for heart disease in athletes by athletic trainers and sports physical therap...
10733236 - Partial cftr genotyping and characterisation of cystic fibrosis patients with myocardia...
24774206 - The right heart in adults with congenital heart disease.
15556016 - Sudden unexpected death of a 17-year-old male infected with the influenza virus.
6970796 - Calculation of viable and infarcted myocardial mass from thallium-201 tomograms.
18246236 - Clinical presentation and outcomes of acute coronary syndromes in the gulf registry of ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  58     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  626-32     Citation Subset:  IM    
*Inserm, U 698, Cardiovascular Remodelling, CHU Xavier Bichat-Claude Bernard, University of Paris Diderot, Paris, France †Faculty of Medicine, Menoufiya University, Menoufiya, Egypt ‡Cardiology Department, CHU Cochin, Paris Descartes University, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Effect of Endothelial Progenitor Cells on Angiotensin II-induced Proliferation of Cultured Rat V...
Next Document:  Potential roles of PI3K/Akt and Nrf2-Keap1 pathways in regulating hormesis of Z-ligustilide in PC12 ...